Cargando…

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells

The introduction of second-generation tyrosine kinase inhibitors (TKIs) targeting the protein-tyrosine kinase (PTK) BCR-ABL1 has improved treatment response in chronic myeloid leukemia (CML). However, in some patients response still remains suboptimal. Protein-tyrosine phosphatases (PTPs) are natura...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drube, Julia, Ernst, Thomas, Pfirrmann, Markus, Albert, Benadict Vincent, Drube, Sebastian, Reich, Daniela, Kresinsky, Anne, Halfter, Kathrin, Sorio, Claudio, Fabisch, Christian, Hochhaus, Andreas, Böhmer, Frank-D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823647/ https://www.ncbi.nlm.nih.gov/pubmed/29507701 http://dx.doi.org/10.18632/oncotarget.24253

Ejemplares similares

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate
por: Klement, Laura, et al.
Publicado: (2023)

Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG
por: Lombardi, Giulia, et al.
Publicado: (2022)

A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease
por: Boni, Christian, et al.
Publicado: (2022)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
por: Ernst, Thomas, et al.
Publicado: (2023)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Identification of Protein Tyrosine Phosphatase Receptor Gamma Extracellular Domain (sPTPRG) as a Natural Soluble Protein in Plasma
por: Moratti, Elisabetta, et al.
Publicado: (2015)

Development and targeted use of nilotinib in chronic myeloid leukemia
por: Fava, Carmen, et al.
Publicado: (2009)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
por: Jabbour, Elias, et al.
Publicado: (2010)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
por: Al-Jafar, Hassan A., et al.
Publicado: (2015)

Characterization of PTPRG in Knockdown and Phosphatase-Inactive Mutant Mice and Substrate Trapping Analysis of PTPRG in Mammalian Cells
por: Zhang, Wandong, et al.
Publicado: (2012)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
por: Piccaluga, Pier Paolo, et al.
Publicado: (2012)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
por: Patel, Vihang, et al.
Publicado: (2017)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
por: Maruta, Shunsuke, et al.
Publicado: (2021)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia
por: Ismail, Abdel-Latif S, et al.
Publicado: (2020)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
por: Al-Dubai, Husam N., et al.
Publicado: (2020)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells
por: Demircan, Muhammed Burak, et al.
Publicado: (2022)

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
por: Giles, Francis J., et al.
Publicado: (2017)

A complicated liaison: IL-33 and IL-33R in arthritis pathogenesis
por: Kamradt, Thomas, et al.
Publicado: (2013)

Aberrant DNA methylation of PTPRG as one possible mechanism of its under‐expression in CML patients in the State of Qatar
por: Ismail, Mohamed A., et al.
Publicado: (2020)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
por: Hochhaus, A, et al.
Publicado: (2016)

Protein tyrosine phosphatase receptor type C (PTPRC or CD45)
por: Al Barashdi, Maryam Ahmed, et al.
Publicado: (2021)

PTPRC functions as a prognosis biomarker in the tumor microenvironment of cutaneous melanoma
por: Li, Xuemei, et al.
Publicado: (2023)

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report
por: Caocci, Giovanni, et al.
Publicado: (2014)

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
por: Sanford, David, et al.
Publicado: (2014)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
por: Cengiz Seval, Güldane, et al.
Publicado: (2017)

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia
por: Kiriyama, Hiroyuki, et al.
Publicado: (2019)

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib
por: Gullaksen, Stein-Erik, et al.
Publicado: (2017)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
por: Hochhaus, A, et al.
Publicado: (2017)

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013)

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
por: Radich, Jerald P., et al.
Publicado: (2021)

Upregulation of PTPRC and Interferon Response Pathways in HIV-1 Seroconverters Prior to Infection
por: Li, Yunqi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hq7a4732p1b3ldv78ms15r4eqm